The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia

We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day....

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Yasuhiro, Takahashi, Naoto, Miura, Masatomo, Hirase, Chikara, Sueda, Sanae, Espinoza, Jorge Luis, Rai, Shinya, Nakayama, Shoko, Serizawa, Kentaro, Kumode, Takahiro, Watatani, Yosaku, Morita, Yasuyoshi, Tanaka, Hirokazu, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691019/
https://www.ncbi.nlm.nih.gov/pubmed/32641651
http://dx.doi.org/10.2169/internalmedicine.4871-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691019/
https://www.ncbi.nlm.nih.gov/pubmed/32641651
http://dx.doi.org/10.2169/internalmedicine.4871-20

Ejemplares similares